Two compounds, Kv1.3 and KCa3.1 (voltage-gated potassium channel and calcium activated potassium channel inhibitors respectively) have shown promising results in animal studies for the treatment of autoimmune diseases such as multiple sclerosis, psoriasis and type-one diabetes may also benefit subjects with CIDP [38,39]. This evidence concerns the gene KCNN4 and autoimmune disease.